Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), for which there are unmet needs surrounding its management. Four posters presented at international congresses in 2019 and 2020 investigated the management of SHPT, including the efficacy and safety of current and future treatments.
EMJ Nephrology 8 [Supplement 3] . 2020
October 2020
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given